Efficacy and Tolerance Study of Bevacizumab in Her2- Inflammatory Breast Cancer Patients
Status:
Completed
Trial end date:
2019-09-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different
ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and
help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy work in
different ways to stop the growth of tumor cells, either by killing the cells or by stopping
them from dividing. Giving bevacizumab and combination chemotherapy before surgery may make
the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving
bevacizumab and radiation therapy after surgery may kill any tumor cells that remain after
surgery.
PURPOSE: This phase II trial is studying giving bevacizumab together with chemotherapy before
surgery and bevacizumab and radiation therapy after surgery to see how well it works in
treating patients with inflammatory breast cancer.